Ponatinib in treatment of chronic myeloid leukemia with T315I mutation
Hematology in Clinical Practice · 2021
DOI: 10.5603/hcp.2021.0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2021. Verfasst von Klaudia Cieśluk und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation t(9;22)(q34;q11) which causes the formation of the Philadelphia chromosome (Ph). Therapeutic progress made in the last two decades and new-generation tyrosine kinase inhibitors (TKIs) introduction, signifi cantly increased patients’ prognosis. We present a case study of a Ph-positive CML patient with a point BCR/ABL1 mutation T315I treated with ponatinib.
Zitieren
APA
Cieśluk, K., & Piszcz, J. (2021). Ponatinib in treatment of chronic myeloid leukemia with T315I mutation. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2021.0006
Vancouver
Cieśluk K, Piszcz J. Ponatinib in treatment of chronic myeloid leukemia with T315I mutation. Hematology in Clinical Practice. 2021. doi:10.5603/hcp.2021.0006
BibTeX
@article{Cieluk2021,
author = {Cieśluk, Klaudia and Piszcz, Jarosław},
title = {Ponatinib in treatment of chronic myeloid leukemia with T315I mutation},
journal = {Hematology in Clinical Practice},
year = {2021},
doi = {10.5603/hcp.2021.0006}
}
EUVIMED